CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Artiva Biotherapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Artiva Biotherapeutics Inc
5505 Morehouse Drive
Phone: (858) 267-4467p:858 267-4467 SAN DIEGO, CA  92121  United States Ticker: ARTVARTV
Business Summary
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board BrianDaniels 65 6/1/2020 6/1/2020
President, Chief Executive Officer, Director FredAslan 49 1/1/2021 1/1/2021
Chief Financial Officer, Executive Vice President - Corporate Development NehaKrishnamohan 37 4/1/2024 4/1/2024
8 additional Officers and Directors records available in full report.

Business Names
Business Name
ARTIVA BIOTHERAPEUTICS
ARTV

General Information
Number of Employees: 82 (As of 9/30/2024)
Outstanding Shares: 24,289,328 (As of 10/31/2024)
Stock Exchange: NASD
Federal Tax Id: 863614316
Fax Number: (302) 269-3855
Email Address: info@artivabio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024